| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.wanbury.com | |
| Market Cap | 212.98 Cr. | |
| Enterprise Value(EV) | 316.74 Cr. | 2021-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -3.07 | Trailing Twelve Months Ending 2021-12 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2021-12 |
| Industry PE | 29.26 | Trailing Twelve Months Ending 2021-12 |
| Book Value / Share | -33.10 | Trailing Twelve Months Ending 2021-12 |
| Price to Book Value | -1.96 | Calculated using Price: 64.95 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 3.27 Cr. | 32,665,498 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Wanbury was incorporated in 1990 as a private limited company under the name of Pearl Distributors Private Limited. The name of the company was changed to 'Pearl Organics Private Limited on January 17, 1991 and the company was converted into a public limited company on August 6, 1991. Wanbury is the fastest growing pharma company amongst top 100 companies in India as per ORG-IMS has strong presence in domestic branded formulations. Wanbury’s major thrust area also lies in Active Pharmaceutical Ingredient (API) and Contract Research and Manufacturing Services (CRAMS). It has a presence in Spain through its branded formulation business - Cantabria Pharma S. L acquired in 2006. The company is having 3 API manufacturing facilities including 2 US FDA approved multi-product API facilities for regulated markets. Product range of the company includes:
Milestones: 2008Wanbury opened an office in Zurich, Switzerland for its CRAMS business. Wanbury incorporated Wanbury Global FZE in Middle East for expanding its global business.Wanbury achieved consolidated turnover of Rs. 630 crore for 18 months period ended 30th September 2008. Rabiplus was awarded ‘Best Brand Launch’ by ORG-IMS as it did sales of Rs.13.8 crores in launch Year. Wanbury is the fastest growing company among top 100 companies in India as per ORG-IMS. 2007Doctor’s Organics Chemicals merged with Wanbury. Wanbury entered into a strategic association with Bravo Healthcare Wanbury incorporated Ningxia Wanbury Fine Chemicals Co to source raw materials from China. Wanbury approved as preferred Vendor by Pfizer (US) for Contract Research and Manufacturing Services (CRAMS). Cpink was awarded ‘Best Brand Launch’ by ORG-IMS as it did sales of Rs. 11 crores in launch year. Wanbury is the fastest growing company among top 100 companies in India as per ORG-IMS. 2006Wanbury achieved 100 crore turnover. Pharmaceutical Products of India (PPIL) merged with Wanbury pursuant to BIFR order. Wanbury acquired Cantabria Pharma S.L. with presence in ethical branded formulations in the Spanish market. Wanbury crossed 1000 employees mark. Wanbury became the world’s largest producer of Metformin with production of 4500 MT. 2005Wanbury acquired Doctor’s Organics and Chemicals, having a US FDA approved facility for manufacturing multi-product API’s. 2004Wander merged with Pearl Organics Limited and Pearl Organics renamed as Wanbury Wanbury set up its R & D center in Navi Mumbai for API. Wanbury started using SAP as a business transaction system. 2002Pearl Organics got US FDA approval for Patalganga plant. 1996Pearl Organics entered into a strategic alliance with Wyckoff Chemicals (US) to market its API in US. 1995Pearl Organics acquired plant of Brij Chemicals Pvt at Patalganga (Maharashtra). 1992Pearl Organics established its first plant in Tarapur for manufacturing API’s. 1991Pearl Distributors Pvt went public and was renamed as Pearl Organics. 1990Incorporated as Pearl Distributors Pvt Achievements/ recognition:-
|
||
Company Profile
Wanbury was incorporated in 1990 as a private limited company under the name of Pearl Distributors Private Limited. The name of the company was changed to 'Pearl Organics Private Limited on January 17, 1991 and the company was converted into a public limited company on August 6, 1991.
Wanbury is the fastest growing pharma company amongst top 100 companies in India as per ORG-IMS has strong presence in domestic branded formulations. Wanbury’s major thrust area also lies in Active Pharmaceutical Ingredient (API) and Contract Research and Manufacturing Services (CRAMS). It has a presence in Spain through its branded formulation business - Cantabria Pharma S. L acquired in 2006.
The company is having 3 API manufacturing facilities including 2 US FDA approved multi-product API facilities for regulated markets.
Product range of the company includes:
Milestones:
2008Wanbury opened an office in Zurich, Switzerland for its CRAMS business. Wanbury incorporated Wanbury Global FZE in Middle East for expanding its global business.Wanbury achieved consolidated turnover of Rs. 630 crore for 18 months period ended 30th September 2008. Rabiplus was awarded ‘Best Brand Launch’ by ORG-IMS as it did sales of Rs.13.8 crores in launch Year. Wanbury is the fastest growing company among top 100 companies in India as per ORG-IMS.
2007Doctor’s Organics Chemicals merged with Wanbury. Wanbury entered into a strategic association with Bravo Healthcare Wanbury incorporated Ningxia Wanbury Fine Chemicals Co to source raw materials from China. Wanbury approved as preferred Vendor by Pfizer (US) for Contract Research and Manufacturing Services (CRAMS). Cpink was awarded ‘Best Brand Launch’ by ORG-IMS as it did sales of Rs. 11 crores in launch year. Wanbury is the fastest growing company among top 100 companies in India as per ORG-IMS.
2006Wanbury achieved 100 crore turnover. Pharmaceutical Products of India (PPIL) merged with Wanbury pursuant to BIFR order. Wanbury acquired Cantabria Pharma S.L. with presence in ethical branded formulations in the Spanish market. Wanbury crossed 1000 employees mark. Wanbury became the world’s largest producer of Metformin with production of 4500 MT.
2005Wanbury acquired Doctor’s Organics and Chemicals, having a US FDA approved facility for manufacturing multi-product API’s.
2004Wander merged with Pearl Organics Limited and Pearl Organics renamed as Wanbury Wanbury set up its R & D center in Navi Mumbai for API. Wanbury started using SAP as a business transaction system.
2002Pearl Organics got US FDA approval for Patalganga plant.
1996Pearl Organics entered into a strategic alliance with Wyckoff Chemicals (US) to market its API in US.
1995Pearl Organics acquired plant of Brij Chemicals Pvt at Patalganga (Maharashtra).
1992Pearl Organics established its first plant in Tarapur for manufacturing API’s.
1991Pearl Distributors Pvt went public and was renamed as Pearl Organics.
1990Incorporated as Pearl Distributors Pvt
Achievements/ recognition:-
| 1 Day |
|
-3.06% |
| 1 Week |
|
-7.21% |
| 1 Month |
|
-23.23% |
| 3 Month |
|
-31.09% |
| 6 Month |
|
-11.87% |
| 1 Year |
|
-37.16% |
| 2 Year |
|
+277.62% |
| 5 Year |
|
+24.78% |
| 10 Year |
|
+259.83% |
| 9 years | 2013-03 | 2014-09 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | ||||||||||
| Return on Capital Employed (%) | -12.92 | -31.06 | 13.85 | 15.27 | 70.48 | -2.00 | 50.26 | 444.45 | ||
| Return on Assets (%) | -11.03 | -21.66 | 0.80 | -1.82 | 15.57 | -9.44 | -9.00 | 23.10 | -4.51 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-09 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-09* Rs. Cr. |
| Shh. Funds | -48 | -192 | -194 | -189 | -153 | -185 | -209 | -143 | -156 | -108 | |
| Non Curr. Liab. | 347 | 312 | 298 | 251 | 160 | 106 | 130 | 108 | 84 | 83 | |
| Curr. Liab. | 447 | 259 | 265 | 299 | 402 | 348 | 362 | 311 | 355 | 379 | |
| Minority Int. | 27 | 27 | 27 | 27 | |||||||
| Equity & Liab. | 773 | 406 | 396 | 388 | 409 | 269 | 283 | 275 | 284 | 354 | |
| Non Curr. Assets | 583 | 219 | 215 | 224 | 217 | 192 | 185 | 182 | 182 | 185 | |
| Curr. Assets | 190 | 187 | 181 | 164 | 192 | 78 | 98 | 94 | 101 | 169 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 773 | 406 | 396 | 388 | 409 | 269 | 283 | 275 | 284 | 354 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-09 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-12 Rs. Cr. TTM |
| Net Sales | 459 | 662 | 250 | 423 | 434 | 371 | 391 | 367 | 393 | 497 | |
| Other Income | 5 | 11 | 6 | 1 | 90 | 77 | 12 | 46 | 5 | 2 | |
| Total Income | 464 | 673 | 256 | 425 | 524 | 448 | 403 | 414 | 397 | 499 | |
| Total Expenditure | -491 | -638 | -229 | -391 | -415 | -439 | -378 | -389 | -377 | -477 | |
| PBIDT | -27 | 35 | 28 | 34 | 108 | 9 | 25 | 25 | 20 | 23 | |
| Interest | -37 | -48 | -19 | -32 | -36 | -31 | -40 | -33 | -23 | -22 | |
| Depreciation | -23 | -23 | -5 | -9 | -10 | -10 | -10 | -10 | -10 | -11 | |
| Taxation | 0 | -3 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Exceptional Items | -89 | 83 | |||||||||
| PAT | -87 | -128 | 3 | -7 | 62 | -32 | -25 | 64 | -13 | -10 | |
| Minority Interest | |||||||||||
| Share Associate | |||||||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | -87 | -128 | 3 | -7 | 62 | -32 | -25 | 64 | -13 | -10 | |
| Adjusted EPS | -50 | -64 | 2 | -4 | 27 | -13 | -10 | 26 | -5 | -4 |
| Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-09 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 9 | 87 | 68 | 40 | 43 | 43 | 32 | 30 | 44 | 17 | |
| Cash Fr. Inv. | -32 | -21 | -6 | -5 | -20 | -13 | -1 | -3 | 64 | 8 | |
| Cash Fr. Finan. | 24 | -64 | -71 | -30 | -28 | -27 | -33 | -27 | -108 | -17 | |
| Net Change | 2 | 3 | -9 | 5 | -5 | 3 | -2 | 0 | 0 | 7 | |
| Cash & Cash Eqvt | 7 | 10 | 1 | 6 | 2 | 5 | 3 | 3 | 3 | 10 |
|
Fri, 20 May 2022
Board Meeting Intimation for Notice Of Board Meeting For Approving The Audited Financial Results & Audited Financial Statements Of The Company For The Last Quarter And Financial Year Ended 31St March 2022. WANBURY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/06/2022 inter alia to consider and approve Notice is hereby given pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 that the meeting of the Board of Directors of Wanbury Limited is scheduled to be held on Wednesday 22nd June 2022 inter-alia to consider and approve the following:1. Audited Financial Results (Standalone & Consolidated) for the last quarter and financial year ended 31st March 2022.2. Audited Financial Statements (Standalone & Consolidated) for the financial year ended 31st March 2022.Further as per Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015 the trading window for dealing in Securities of the Company shall remain closed for the Companys Directors/Officers/Key Managerial Personnel/Designated Employees of the Company w.e.f. 1st April 2022 till the close of business hours on 24th June 2022 |
|
Fri, 15 Apr 2022
Certificate Under Regulation 40(9) Of The Listing Regulations For The Year Ended On 31St March 2022. Pursuant to Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we are enclosing herewith the Compliance Certificate for the period from1s1 April 2021 to 31st March 2022 received from Ms. Kala Agarwal Practicing Company Secretary. Kindly take the same on your records and acknowledge the receipt. |
|
Fri, 08 Apr 2022
Large Corporate Entity_Initial Pursuant to the SEBI Circular No.: SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018 regarding Fund Raising by Issuance of Debt Securities by Large Entities; this is to confirm that the Company does not fall in the criteria mentioned under the said Circular and therefore does not qualify as Large Corporate.Kindly take the same on your records and acknowledge the receipt. |
| Fri, 20 May 2022 |
Higher Delivery Quantity
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
Closing Below Previous Low
|
Closing Below Previous Low for 3 days
|
Equities
M.F.
Sectors